Sclerotherapy for Reticular Veins in the Lower Limbs
Open Access
- 1 December 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (12), 1249-1255
- https://doi.org/10.1001/jamadermatol.2017.3426
Abstract
Reticular veins are flat and bluish subdermal veins less than 4 mm in diameter located in the lower limbs.1,2 They have been designated as class 1 (C1) by the American Venous Forum3 in the CEAP (clinical, etiologic, anatomic, and pathophysiologic) classification system. The prevalence of reticular veins is extremely high, reaching up to 60% in some populations, being more common in women, and increasing with age.4 Their etiology is attributed to failure of microvenous valves5,6 and/or transmission of reflux from incompetent superficial venous systems.7Keywords
This publication has 38 references indexed in Scilit:
- Myocardial infarction after ultrasoundguided foam sclerotherapy for varicose veins - a case report and review of the literature of a rare but serious adverse eventVasa, 2016
- Consensus for SclerotherapyDermatologic Surgery, 2014
- Guidelines for the Management of Varicose VeinsPhlebology: The Journal of Venous Disease, 2012
- Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study)Phlebology: The Journal of Venous Disease, 2010
- Epidemiology of chronic venous diseasePhlebology: The Journal of Venous Disease, 2008
- Valves in Small Veins and VenulesEuropean Journal of Vascular and Endovascular Surgery, 2006
- Double-Blind Prospective Comparative Trial between Foamed and Liquid Polidocanol and Sodium Tetradecyl Sulfate in the Treatment of Varicose and Telangiectatic Leg VeinsDermatologic Surgery, 2006
- Revision of the CEAP classification for chronic venous disorders: Consensus statementJournal of Vascular Surgery, 2004
- Cutaneous Necrosis, Telangiectatic Matting, and Hyperpigmentation following Sclerotherapy Etiology, Prevention, and TreatmentDermatologic Surgery, 1995
- [66% glucose, a safe sclerosant. Experimental study].1984